Yu Ning, Li Yajing, Han Xue, Sun Yuan, Li Yun, Gao Yanjun, Zhang Xiaoxuan
Department of Neurology, Affiliated Hospital of Chengde Medical University, Chengde, Hebei Province, China.
Brain Behav. 2025 May;15(5):e70552. doi: 10.1002/brb3.70552.
To investigate the effect of probucol and atorvastatin on self-care ability in patients with acute cerebral infarction (ACI).
Eighty-one patients with ACI admitted from November 2020 to May 2021 were divided into a combination treatment group (n = 40) and an atorvastatin group (n = 41). The atorvastatin group was given atorvastatin on the basis of conventional treatment, and the combination treatment group was treated with probucol and atorvastatin on the control basis. Self-care ability and blood lipid levels were assessed at baseline and 6 months after treatment using the Barthel Index (BI) and biochemical tests. The study also included MRI scans to evaluate infarct volume and monitored relevant clinical indicators.
The baseline data of both groups were consistent and comparable. After six months, both groups showed improved self-care ability, with the combined treatment group exhibiting a more significant improvement (P < 0.05). The combination treatment group also demonstrated a significant reduction in total cholesterol (TCH) and low-density lipoprotein (LDL) levels compared to the atorvastatin group (P < 0.05). The factors influencing self-care ability included history of cerebrovascular disease, treatment modality, and LDL levels.
Probucol combined with atorvastatin significantly enhances self-care ability and improves blood lipid levels in patients with ACI. This combination therapy is safe, feasible, and recommended for clinical application to reduce cognitive decline and improve quality of life in these patients.
探讨普罗布考与阿托伐他汀对急性脑梗死(ACI)患者自我护理能力的影响。
选取2020年11月至2021年5月收治的81例ACI患者,分为联合治疗组(n = 40)和阿托伐他汀组(n = 41)。阿托伐他汀组在常规治疗基础上给予阿托伐他汀,联合治疗组在对照基础上采用普罗布考与阿托伐他汀治疗。治疗前及治疗6个月后,采用Barthel指数(BI)和生化检测评估自我护理能力和血脂水平。该研究还包括MRI扫描以评估梗死体积,并监测相关临床指标。
两组基线数据一致且具有可比性。6个月后,两组自我护理能力均有所提高,联合治疗组改善更为显著(P < 0.05)。与阿托伐他汀组相比,联合治疗组总胆固醇(TCH)和低密度脂蛋白(LDL)水平也显著降低(P < 0.05)。影响自我护理能力的因素包括脑血管疾病史、治疗方式和LDL水平。
普罗布考联合阿托伐他汀可显著提高ACI患者的自我护理能力并改善血脂水平。这种联合治疗安全、可行,推荐临床应用以减少这些患者的认知功能下降并提高生活质量。